These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 34115855)

  • 1. Survival of chemo-naïve patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404.
    Ninomiya T; Nogami N; Kozuki T; Harada D; Kubo T; Ohashi K; Ichihara E; Kuyama S; Kudo K; Bessho A; Sakugawa M; Fujimoto N; Aoe K; Minami D; Sugimoto K; Ochi N; Takigawa N; Hotta K; Maeda Y; Kiura K
    Jpn J Clin Oncol; 2021 Aug; 51(8):1269-1276. PubMed ID: 34115855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404.
    Ninomiya T; Nogami N; Kozuki T; Harada D; Kubo T; Ohashi K; Kuyama S; Kudo K; Bessho A; Fukamatsu N; Fujimoto N; Aoe K; Shibayama T; Sugimoto K; Takigawa N; Hotta K; Kiura K
    Lung Cancer; 2018 Jan; 115():103-108. PubMed ID: 29290249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study).
    Hata A; Katakami N; Kaji R; Yokoyama T; Kaneda T; Tamiya M; Inoue T; Kimura H; Yano Y; Tamura D; Morita S; Negoro S; The Hanshin Oncology Group F
    Cancer; 2018 Oct; 124(19):3830-3838. PubMed ID: 30192383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403.
    Oda N; Hotta K; Ninomiya K; Minami D; Ichihara E; Murakami T; Yokoyama T; Ichikawa H; Chikamori K; Takigawa N; Ochi N; Harita S; Maeda Y; Kiura K
    Cancer Chemother Pharmacol; 2018 Dec; 82(6):1031-1038. PubMed ID: 30276451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402).
    Yokoyama T; Yoshioka H; Fujimoto D; Demura Y; Hirano K; Kawai T; Kagami R; Washio Y; Ishida T; Kogo M; Tomii K; Okuno T; Akai M; Hirabayashi M; Nishimura T; Nakahara Y; Kim YH; Miyakoshi C; Yoshimura K; Hirai T;
    Lung Cancer; 2019 Sep; 135():175-180. PubMed ID: 31446992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2 Study of Afatinib Alone or Combined With Bevacizumab in Chemonaive Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: AfaBev-CS Study Protocol.
    Ninomiya T; Ishikawa N; Inoue K; Kubo T; Yasugi M; Shibayama T; Maeda T; Fujitaka K; Kodani M; Yokoyama T; Kuyama S; Ochi N; Ueda Y; Miyoshi S; Kozuki T; Amano Y; Kubota T; Sugimoto K; Bessho A; Ishii T; Watanabe K; Oze I; Hotta K; Kiura K
    Clin Lung Cancer; 2019 Mar; 20(2):134-138. PubMed ID: 30514667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027.
    Minegishi Y; Yamaguchi O; Sugawara S; Kuyama S; Watanabe S; Usui K; Mori M; Hataji O; Nukiwa T; Morita S; Kobayashi K; Gemma A
    BMC Cancer; 2021 Mar; 21(1):208. PubMed ID: 33648453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.
    Rosell R; Dafni U; Felip E; Curioni-Fontecedro A; Gautschi O; Peters S; Massutí B; Palmero R; Aix SP; Carcereny E; Früh M; Pless M; Popat S; Kotsakis A; Cuffe S; Bidoli P; Favaretto A; Froesch P; Reguart N; Puente J; Coate L; Barlesi F; Rauch D; Thomas M; Camps C; Gómez-Codina J; Majem M; Porta R; Shah R; Hanrahan E; Kammler R; Ruepp B; Rabaglio M; Kassapian M; Karachaliou N; Tam R; Shames DS; Molina-Vila MA; Stahel RA;
    Lancet Respir Med; 2017 May; 5(5):435-444. PubMed ID: 28408243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma.
    Huang YH; Hsu KH; Chin CS; Tseng JS; Yang TY; Chen KC; Su KY; Yu SL; Chen JJW; Chang GC
    Cancer Res Treat; 2022 Apr; 54(2):434-444. PubMed ID: 34352999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized phase II study of afatinib alone or combined with bevacizumab for treating chemo-naïve patients with non-small cell lung cancer harboring EGFR mutations.
    Ninomiya T; Ishikawa N; Kozuki T; Kuyama S; Inoue K; Yokoyama T; Kanaji N; Yasugi M; Shibayama T; Aoe K; Ochi N; Fujitaka K; Kodani M; Ueda Y; Watanabe K; Bessho A; Sugimoto K; Oze I; Hotta K; Kiura K
    Lung Cancer; 2023 Oct; 184():107349. PubMed ID: 37651927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs.
    Park JS; Hong MH; Chun YJ; Kim HR; Cho BC
    Lung Cancer; 2019 Aug; 134():46-51. PubMed ID: 31319994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-Line Afatinib plus Cetuximab for
    Cortot AB; Madroszyk A; Giroux-Leprieur E; Molinier O; Quoix E; Bérard H; Otto J; Rault I; Moro-Sibilot D; Raimbourg J; Amour E; Morin F; Hureaux J; Moreau L; Debieuvre D; Morel H; Renault A; Pichon E; Huret B; Charpentier S; Denis MG; Cadranel J
    Clin Cancer Res; 2021 Aug; 27(15):4168-4176. PubMed ID: 34031056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
    Horn L; Gettinger S; Camidge DR; Smit EF; Janjigian YY; Miller VA; Pao W; Freiwald M; Fan J; Wang B; Chand VK; Groen HJM
    Lung Cancer; 2017 Nov; 113():51-58. PubMed ID: 29110849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study.
    de Marinis F; Laktionov KK; Poltoratskiy A; Egorova I; Hochmair M; Passaro A; Migliorino MR; Metro G; Gottfried M; Tsoi D; Ostoros G; Rizzato S; Mukhametshina GZ; Schumacher M; Novello S; Dziadziuszko R; Tang W; Clementi L; Cseh A; Kowalski D
    Lung Cancer; 2021 Feb; 152():127-134. PubMed ID: 33387727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective, phase II trial of monotherapy with low-dose afatinib for patients with EGFR, mutation-positive, non-small cell lung cancer: Thoracic oncology research group 1632.
    Noro R; Igawa S; Bessho A; Hirose T; Shimokawa T; Nakashima M; Minato K; Seki N; Tokito T; Harada T; Sasada S; Miyamoto S; Tanaka Y; Furuya N; Kaburagi T; Hayashi H; Iihara H; Okamoto H; Kubota K
    Lung Cancer; 2021 Nov; 161():49-54. PubMed ID: 34536731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Afatinib + bevacizumab combination therapy in EGFR-mutant NSCLC patients with osimertinib resistance: Protocol of an open-label, phase II, multicenter, single-arm trial.
    Kobayashi N; Hashimoto H; Kamimaki C; Nagasawa R; Tanaka K; Kubo S; Katakura S; Chen H; Hirama N; Ushio R; Aoki A; Nakashima K; Teranishi S; Manabe S; Watanabe H; Horita N; Watanabe K; Hara Y; Yamamoto M; Kudo M; Piao H; Kaneko T
    Thorac Cancer; 2020 Aug; 11(8):2125-2129. PubMed ID: 32495514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of
    Goldberg SB; Redman MW; Lilenbaum R; Politi K; Stinchcombe TE; Horn L; Chen EH; Mashru SH; Gettinger SN; Melnick MA; Herbst RS; Baumgart MA; Miao J; Moon J; Kelly K; Gandara DR
    J Clin Oncol; 2020 Dec; 38(34):4076-4085. PubMed ID: 33021871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.
    Moran T; Palmero R; Provencio M; Insa A; Majem M; Reguart N; Bosch-Barrera J; Isla D; Costa EC; Lee C; Puig M; Kraemer S; Schnell D; Rosell R
    Lung Cancer; 2017 Jun; 108():154-160. PubMed ID: 28625629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.